Eli Lilly And Co (NYSE:LLY) Shares Sold by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC trimmed its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 13.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 389,480 shares of the company’s stock after selling 60,073 shares during the period. Nisa Investment Advisors LLC’s holdings in Eli Lilly And Co were worth $43,150,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. FMR LLC lifted its stake in Eli Lilly And Co by 1.7% during the 1st quarter. FMR LLC now owns 13,916,001 shares of the company’s stock valued at $1,805,741,000 after acquiring an additional 228,920 shares during the period. Geode Capital Management LLC lifted its stake in Eli Lilly And Co by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock valued at $1,514,582,000 after acquiring an additional 830,689 shares during the period. Norges Bank acquired a new stake in Eli Lilly And Co during the 4th quarter valued at approximately $1,056,086,000. California Public Employees Retirement System lifted its stake in Eli Lilly And Co by 8.1% during the 1st quarter. California Public Employees Retirement System now owns 3,162,898 shares of the company’s stock valued at $410,418,000 after acquiring an additional 238,198 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its stake in Eli Lilly And Co by 5.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 3,080,350 shares of the company’s stock valued at $399,706,000 after acquiring an additional 156,321 shares during the period. Institutional investors and hedge funds own 79.38% of the company’s stock.
Several analysts have commented on LLY shares. Goldman Sachs Group set a $27.00 price objective on shares of Melco Resorts & Entertainment and gave the company a “buy” rating in a research note on Tuesday, May 28th. ValuEngine cut shares of WideOpenWest from a “hold” rating to a “sell” rating in a research note on Friday, June 28th. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a research note on Tuesday, April 23rd. TheStreet cut shares of Trade Desk from a “b-” rating to a “c-” rating in a research note on Thursday, May 9th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $45.00 target price on shares of SAP in a report on Wednesday, May 1st. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and a consensus target price of $123.49.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.01. The firm had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 EPS. As a group, equities research analysts forecast that Eli Lilly And Co will post 5.66 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.38%. The ex-dividend date is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.
In related news, SVP Christi Shaw sold 7,577 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $117.14, for a total value of $887,569.78. Following the completion of the sale, the senior vice president now owns 500 shares of the company’s stock, valued at approximately $58,570. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the sale, the vice president now directly owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by insiders.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.